coumarin has been researched along with Bleeding in 66 studies
2H-chromen-2-one: coumarin derivative
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 9.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 9.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "Following the results of clinical studies that only used an elevated INR as a surrogate end-point for the risk of bleeding, low dose oral vitamin K appears as the preferable strategy for rapidly restoring therapeutic INR levels in asymptomatic patients who present with an excessively prolonged INR due to warfarin therapy." | 8.82 | Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. ( Ageno, W; Dentali, F, 2004) |
| "To investigate the risk of bleeding complications during the combined use of coumarin derivatives and nonsteroidal antiinflammatory drugs (NSAIDs) compared with the use of coumarin derivatives alone." | 7.72 | Concomitant coumarin-NSAID therapy and risk for bleeding. ( Knijff-Dutmer, EA; Schut, GA; van de Laar, MA, 2003) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 7.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "Hemorrhagic skin necrosis of the toes was observed in a patient with heterozygous protein C deficiency (protein C:Ag 32% and protein C activity 30%) on the 4th day of coumarin treatment overlapping with effective intravenous anticoagulation with heparin." | 7.67 | Coumarin induced acral skin necrosis associated with hereditary protein C deficiency. ( Karnik, R; Lechner, K; Niessner, H; Pabinger, I; Slany, J, 1986) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Patients with thrombolysis in myocardial infarction (TIMI) 3 flow <48 hours after fibrinolysis for ST-elevation myocardial infarction were randomized to aspirin plus coumarin, with prolonged heparinization until the target international normalized ratio (2-3) was reached, or aspirin with standard heparinization." | 5.14 | Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. ( Aengevaeren, WR; Brouwer, MA; Kievit, PC; van den Bergh, PJ; Veen, G; Verheugt, FW, 2009) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 5.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 5.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "To evaluate the impact of the CYP4F2 polymorphism on bleeding complications and over-anticoagulation due to coumarin." | 4.93 | Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients. ( Chen, P; Li, R; Pan, J; Sun, YQ; Yang, GP; Zhou, YS, 2016) |
| "Following the results of clinical studies that only used an elevated INR as a surrogate end-point for the risk of bleeding, low dose oral vitamin K appears as the preferable strategy for rapidly restoring therapeutic INR levels in asymptomatic patients who present with an excessively prolonged INR due to warfarin therapy." | 4.82 | Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. ( Ageno, W; Dentali, F, 2004) |
| " The present study focused on exploring the genetic etiology of idiopathic hyper sensitivity to coumarin anticoagulants in a patient who presented with multiple bleeding episodes and supra-elevated International Normalized Ratios." | 3.79 | Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity. ( Deb, R; Dube, D; Nahar, R; Parakh, R; Saxena, R; Singh, TP; Verma, IC, 2013) |
| "Warfarin and acenocoumarols are the most commonly prescribed anticoagulants that is difficult to use because of the wide intra- and interpatient variation in the dose requirements, the narrow therapeutic range and the risk of serious bleeding." | 3.74 | [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy]. ( Melegh, B; Sipeky, C, 2008) |
| "To investigate the risk of bleeding complications during the combined use of coumarin derivatives and nonsteroidal antiinflammatory drugs (NSAIDs) compared with the use of coumarin derivatives alone." | 3.72 | Concomitant coumarin-NSAID therapy and risk for bleeding. ( Knijff-Dutmer, EA; Schut, GA; van de Laar, MA, 2003) |
| " The major drawback of coumarin therapy is the increased risk of hemorrhage." | 3.72 | Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. ( Rosendaal, FR; Torn, M; van der Meer, FJ, 2004) |
| "A previous case-control study involving concomitant users of coumarin and nonsteroidal anti-inflammatory drugs (NSAIDs) found that cyclooxygenase 2 (COX-2)-selective NSAIDs were associated with fewer bleeding complications than nonselective NSAIDs." | 3.72 | Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. ( Brouwers, JR; Knijff-Dutmer, EA; Postma, MJ; van de Laar, MA; van der Palen, J, 2004) |
| "Anticoagulant treatment with coumarins is due to it unequivocal benefit and relatively low risk increasingly used for prevention of sudden cerebrovascular attacks, in atrial fibrillation, in the treatment of thromboembolic disease, as part of treatment after replacement of cardiac valves and other diseases." | 3.70 | [Retroperitoneal hematoma and femoral compression neuropathy--a complication of anticoagulation therapy after myocardial infarct]. ( Gonsorcík, J; Jonás, P; Jurgová, T; Kristian, P; Kucinský, R; Lazúr, J; Tokarcíková, A; Tomasch, J, 1998) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 3.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "Hemorrhagic skin necrosis of the toes was observed in a patient with heterozygous protein C deficiency (protein C:Ag 32% and protein C activity 30%) on the 4th day of coumarin treatment overlapping with effective intravenous anticoagulation with heparin." | 3.67 | Coumarin induced acral skin necrosis associated with hereditary protein C deficiency. ( Karnik, R; Lechner, K; Niessner, H; Pabinger, I; Slany, J, 1986) |
| "One fatal suspected pulmonary embolism in a patient with metastatic cancer was judged to be possibly PCC-related." | 2.73 | Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. ( Brenner, B; Kalina, U; Knaub, S; Nagy, A; Ostermann, H; Pabinger, I, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (50.00) | 18.7374 |
| 1990's | 5 (7.58) | 18.2507 |
| 2000's | 19 (28.79) | 29.6817 |
| 2010's | 9 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woodruff, S | 1 |
| Lee, AYY | 1 |
| Carrier, M | 1 |
| Feugère, G | 1 |
| Abreu, P | 1 |
| Heissler, J | 1 |
| Nahar, R | 1 |
| Dube, D | 1 |
| Parakh, R | 1 |
| Deb, R | 1 |
| Saxena, R | 1 |
| Singh, TP | 1 |
| Verma, IC | 1 |
| Li, X | 1 |
| Vink, A | 2 |
| Niessen, HW | 1 |
| Kers, J | 1 |
| de Boer, OJ | 1 |
| Ploegmakers, HJ | 1 |
| Tijssen, JG | 1 |
| de Winter, RJ | 1 |
| van der Wal, AC | 2 |
| Self, TH | 1 |
| Oliphant, CS | 1 |
| Reaves, AB | 1 |
| Richardson, AM | 1 |
| Sands, CW | 1 |
| Chen, P | 1 |
| Sun, YQ | 1 |
| Yang, GP | 1 |
| Li, R | 1 |
| Pan, J | 1 |
| Zhou, YS | 1 |
| Schalekamp, T | 1 |
| Maitland-van der Zee, AH | 1 |
| de Boer, A | 1 |
| Sipeky, C | 1 |
| Melegh, B | 1 |
| CHENEY, G | 1 |
| van den Bergh, PJ | 2 |
| Kievit, PC | 1 |
| Brouwer, MA | 2 |
| Aengevaeren, WR | 2 |
| Veen, G | 2 |
| Verheugt, FW | 2 |
| Derksen, WJ | 1 |
| Peeters, W | 1 |
| Tersteeg, C | 1 |
| de Vries, JP | 1 |
| de Kleijn, DP | 1 |
| Moll, FL | 1 |
| Pasterkamp, G | 1 |
| Makris, M | 1 |
| Van Veen, JJ | 1 |
| Reininghaus, EZ | 1 |
| Schmidt, H | 1 |
| Lafer, I | 1 |
| Gutjahr, G | 1 |
| Schmidt, SM | 1 |
| Reininghaus, B | 1 |
| Kapfhammer, HP | 1 |
| Stepan, V | 1 |
| Wijnen, PA | 1 |
| Verschakelen, JA | 1 |
| Bast, A | 1 |
| Bekers, O | 1 |
| Drent, M | 1 |
| Luijten, HE | 1 |
| Hertzberger, DP | 1 |
| van Boven, AJ | 1 |
| Vromans, RP | 1 |
| Uijen, GJ | 1 |
| Escobar, MA | 1 |
| Knijff-Dutmer, EA | 2 |
| Schut, GA | 1 |
| van de Laar, MA | 2 |
| ROSE, OA | 1 |
| OTT, RH | 1 |
| MAIER, HC | 1 |
| COSGRIFF, SW | 1 |
| MENDELSOHN, SN | 1 |
| IGLAUER, A | 1 |
| LACHAINE, G | 1 |
| KOCH, H | 1 |
| RAINIE, RC | 1 |
| VERHAGEN, H | 1 |
| ARIEFF, AJ | 1 |
| PYZIK, SW | 1 |
| DONALD, AC | 1 |
| HUNTER, RB | 1 |
| TUDHOPE, GR | 1 |
| WALKER, W | 1 |
| WHITTON, I | 1 |
| BENTLEY, WB | 1 |
| CLOWARD, RB | 1 |
| YUHL, ET | 1 |
| DE DOMINICIS, E | 1 |
| ROLANDI, L | 1 |
| KUSHELEVSKII, BP | 1 |
| THEDERING, F | 1 |
| BOWING, G | 1 |
| JORDAL, R | 1 |
| IMDAHL, H | 2 |
| GOODMAN, DH | 1 |
| SISE, HS | 1 |
| LAVELLE, SM | 1 |
| ADAMIS, D | 1 |
| BECKER, R | 1 |
| PEYMAN, MA | 1 |
| HARRISON, CE | 1 |
| SPITTEL, JA | 1 |
| WAUGH, JM | 1 |
| LOELIGER, EA | 1 |
| HENSEN, A | 1 |
| MATTERN, MJ | 1 |
| HEMKER, HC | 1 |
| MAYER, GA | 1 |
| JORGENSEN, G | 1 |
| STAHL, H | 1 |
| KRESBACH, H | 1 |
| LEVINE, HJ | 1 |
| RYAN, HE | 1 |
| GRIPE, RP | 1 |
| AXELROD, M | 1 |
| KLEINFELD, M | 1 |
| TWYMAN, JB | 1 |
| O'Donnell, M | 1 |
| Hirsh, J | 1 |
| Torn, M | 1 |
| van der Meer, FJ | 1 |
| Rosendaal, FR | 1 |
| Dentali, F | 1 |
| Ageno, W | 1 |
| Postma, MJ | 1 |
| van der Palen, J | 1 |
| Brouwers, JR | 1 |
| Penka, M | 1 |
| Buliková, A | 1 |
| Gumulec, J | 1 |
| Matýsková, M | 1 |
| Smejkal, P | 1 |
| Kissová, J | 1 |
| Slechtová, M | 1 |
| Chlupová, G | 1 |
| Sas, G | 1 |
| Pabinger, I | 2 |
| Brenner, B | 1 |
| Kalina, U | 1 |
| Knaub, S | 1 |
| Nagy, A | 1 |
| Ostermann, H | 1 |
| Ulrich, S | 1 |
| Brand, B | 1 |
| Speich, R | 1 |
| Oldenburg, J | 2 |
| Asmis, L | 1 |
| Crowther, MA | 1 |
| Warkentin, TE | 1 |
| Tamir, A | 1 |
| Wolf, R | 1 |
| Brenner, S | 1 |
| Monreal, M | 1 |
| Lafoz, E | 1 |
| Olive, A | 1 |
| del Rio, L | 1 |
| Vedia, C | 1 |
| Lecuru, F | 1 |
| Desnos, M | 1 |
| Taurelle, R | 1 |
| Jansson, JH | 1 |
| Westman, G | 1 |
| Boman, K | 1 |
| Nilsson, T | 1 |
| Norberg, B | 1 |
| Kristian, P | 1 |
| Kucinský, R | 1 |
| Gonsorcík, J | 1 |
| Jonás, P | 1 |
| Tokarcíková, A | 1 |
| Lazúr, J | 1 |
| Jurgová, T | 1 |
| Tomasch, J | 1 |
| Watzke, HH | 1 |
| Forberg, E | 1 |
| Svolba, G | 1 |
| Jimenez-Boj, E | 1 |
| Krinninger, B | 1 |
| Bharat, V | 1 |
| Mohanty, B | 1 |
| Bestmann, L | 1 |
| Züger, M | 1 |
| Bühler, D | 1 |
| Maly, FE | 1 |
| Ickx, BE | 1 |
| Monhart, V | 1 |
| Sobota, J | 1 |
| Duveau, D | 1 |
| Karnik, R | 1 |
| Lechner, K | 1 |
| Slany, J | 1 |
| Niessner, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Tolerance of BERIPLEX® P/N in Subjects With Acquired Deficiency of Coagulation Factors II, VII, IX and X Due to Oral Anticoagulation[NCT00168077] | Phase 3 | 40 participants | Interventional | 2005-09-30 | Completed | ||
| Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery, Compared With Fresh Frozen Plasma: Study Protocol for a Non-inferiority, Randomized Controlled Trial[NCT04244981] | Phase 4 | 796 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for coumarin and Bleeding
| Article | Year |
|---|---|
Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.
Topics: Acenocoumarol; Animals; Anticoagulants; Clinical Trials as Topic; Coumarins; Fever; Hemorrhage; Huma | 2015 |
Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.
Topics: Anticoagulants; Coumarins; Cytochrome P450 Family 4; Hemorrhage; Humans; International Normalized Ra | 2016 |
Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review.
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Costs and Cost Analysis; Couma | 2004 |
[The preparation of a patient with long-term anticoagulant cumarin treatment for invasive surgery].
Topics: Anticoagulants; Coumarins; Hemorrhage; Humans; International Normalized Ratio; Postoperative Hemorrh | 2006 |
[Old burdens and new perspectives of the long-term anticoagulant therapy].
Topics: Anticoagulants; Azetidines; Benzylamines; Coumarins; Drug Administration Schedule; Hemorrhage; Hepar | 2006 |
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.
Topics: Anticoagulants; Coumarins; Disease Management; Hemorrhage; Heparin; Humans; Risk | 2008 |
Preoperative stop or continue? New antithrombotic and anticoagulants.
Topics: Anticoagulants; Coumarins; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Platelet Aggr | 2001 |
7 trials available for coumarin and Bleeding
| Article | Year |
|---|---|
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm | 2009 |
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Disease-Free Survival; D | 2002 |
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Drug Combinations; Emergencies; Europe; F | 2008 |
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Drug Combinations; Emergencies; Europe; F | 2008 |
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Drug Combinations; Emergencies; Europe; F | 2008 |
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coumarins; Drug Combinations; Emergencies; Europe; F | 2008 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan | 1994 |
Anticoagulant therapy in pregnancy. Report of 54 cases.
Topics: Adult; Anticoagulants; Chi-Square Distribution; Coumarins; Female; Fetus; Heart Valve Prosthesis; He | 1996 |
A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.
Topics: Administration, Oral; Adult; Aged; Algorithms; Anticoagulants; Blood Coagulation; Case Management; C | 2000 |
52 other studies available for coumarin and Bleeding
| Article | Year |
|---|---|
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
Topics: Acenocoumarol; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Base Sequence; Binding Sites; Coumarin | 2013 |
Total burden of intraplaque hemorrhage in coronary arteries relates to the use of coumarin-type anticoagulants but not platelet aggregation inhibitors.
Topics: Aged; Anticoagulants; Autopsy; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Couma | 2014 |
Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2C9; Drug Resistance; | 2008 |
[Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy].
Topics: Adult; Anticoagulants; Coumarins; Female; Haplotypes; Hemorrhage; Humans; Hungary; Male; Middle Aged | 2008 |
An instructive case of dicumarol hemorrhage.
Topics: Coumarins; Dicumarol; Hemorrhage | 1947 |
Age and coumarin-type anticoagulation are associated with the occurrence of intraplaque hemorrhage, while statins are associated less with intraplaque hemorrhage: a large histopathological study in carotid and femoral plaques.
Topics: Age Factors; Aged; Anticoagulants; Carotid Arteries; Coumarins; Endarterectomy; Endarterectomy, Caro | 2011 |
Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?
Topics: Animals; Anticoagulants; Blood Coagulation; Coumarins; Hemorrhage; Humans; Prothrombin | 2011 |
Outcome of coumarin-therapy in an outpatient setting over a 10-year period: coumarin-therapy in clinical practice.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Austria; Comorbidity; Coumarins; Drug-Rela | 2012 |
Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Coumarins; Female; Hemorrhage; | 2013 |
Reversal of coumarin-induced over-anticoagulation.
Topics: Anticoagulants; Coumarins; Factor VIIa; Hemorrhage; Humans; Recombinant Proteins | 2002 |
Concomitant coumarin-NSAID therapy and risk for bleeding.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cohort Stud | 2003 |
Hemopericardium with tamponade during anticoagulant therapy of myocardial infarct; report of a case with recovery following pericardiotomy.
Topics: Anticoagulants; Coumarins; Hemorrhage; Myocardial Infarction; Pericardial Effusion; Pericardiectomy; | 1953 |
Hemorrhage due to self-medication with bishydroxycoumarin.
Topics: Coumarins; Dicumarol; Hemorrhage; Self Medication | 1953 |
Acute abdominal condition due to bishydroxycoumarin (dicumarol) poisoning.
Topics: Abdomen; Acute Disease; Coumarins; Dicumarol; Gastrointestinal Diseases; Hemorrhage | 1953 |
[A strange accident due to anticoagulant medication].
Topics: Accidents; Anticoagulants; Coumarins; Hematoma; Hemorrhage; Humans; Myocardial Infarction; Thigh | 1953 |
Hemorrhage following excessive dosage of dicumarol.
Topics: Coumarins; Dicumarol; Hematoma; Hemorrhage; Humans; Mouth; Oral Hemorrhage | 1953 |
Complications of anticoagulant therapy: review of the literature and report of a case.
Topics: Anticoagulants; Coumarins; Hemorrhage; Humans; Thrombophlebitis | 1954 |
Local haemorrhage and necrosis of the skin and underlying tissues, during anti-coagulant therapy with dicumarol or dicumacyl.
Topics: Coagulants; Coumarins; Dicumarol; Gangrene; Hemorrhage; Humans; Necrosis; Skin | 1954 |
Paraplegia following or associated with excessive dicumarol therapy.
Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Paraplegia; Spinal Cord; Spinal Cord Vascular Diseases | 1954 |
Prothrombin and haemorrhage.
Topics: Blood Coagulation; Coumarins; Hemorrhage; Hemostatics; Humans; Liver Diseases; Prothrombin; Prothrom | 1954 |
Accidental ingestion of bishydroxycoumarin: use of vitamin K1 emulsion in two cases.
Topics: Antifibrinolytic Agents; Coumarins; Dicumarol; Hemorrhage; Naphthoquinones; Poisoning; Retinoids; Vi | 1954 |
Spontaneous intraspinal hemorrhage and paraplegia complicating dicumarol therapy.
Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Myocardial Infarction; Paraplegia; Spinal Cord | 1955 |
[Phenylpropyl hydroxycoumarin as anticoagulant in obstetric and gynecological thrombophlebitis and its antidote, vitamin K1].
Topics: Anticoagulants; Antidotes; Coumarins; Female; Genital Diseases, Female; Hemorrhage; Humans; Thrombop | 1955 |
[Excessive dosage of dicumarol and management of clinical manifestations and therapy of resulting hemorrhage].
Topics: Coumarins; Dicumarol; Disease Management; Hemorrhage | 1956 |
[Decrease of hemorrhagic accidents in anticoagulant therapy with coumarin derivatives by administration of vitamin K1].
Topics: Accidents; Anticoagulants; Antifibrinolytic Agents; Coumarins; Hemorrhage; Humans; Thrombosis; Vitam | 1956 |
Necrosing cutaneous haemorrhages as a complication in dicumarol treatment.
Topics: Administration, Cutaneous; Coumarins; Dicumarol; Gangrene; Hemorrhage; Necrosis; Skin | 1956 |
[Hemorrhage due to coumarin derivatives].
Topics: Coumarins; Hemorrhage | 1956 |
[Hemorrhage due to coumarin derivatives].
Topics: Coumarins; Hemorrhage | 1956 |
[Hemorrhage due to coumarin derivatives].
Topics: Coumarins; Hemorrhage | 1956 |
[Hemorrhage due to coumarin derivatives].
Topics: Coumarins; Hemorrhage | 1956 |
Early clue to visceral carcinoma-hemorrhage after intravenously given warfarin.
Topics: Coumarins; Hemorrhage; Humans; Neoplasms; Warfarin | 1958 |
Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants.
Topics: Anticoagulants; Coumarins; Hemorrhage; Humans; Prothrombin; Prothrombin Time; Thrombosis | 1958 |
The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants.
Topics: Anticoagulants; Coumarins; Hemorrhage; Humans | 1958 |
Coumarin anticoagulant therapy of patients with T-tube drainage of the common bile duct.
Topics: Anticoagulants; Cholelithiasis; Common Bile Duct; Coumarins; Drainage; Hemorrhage; Humans; Thromboem | 1961 |
BEHAVIOUR OF FACTORS II, VII, IX AND X IN BLEEDING COMPLICATIONS DURING LONG-TERM TREATMENT WITH COUMARIN.
Topics: Cerebral Hemorrhage; Coumarins; Epistaxis; Factor VII Deficiency; Hemophilia B; Hemorrhage; Hemorrha | 1964 |
A RARE COMPLICATION OF COUMARIN-CONGENER ANTICOAGULANT THERAPY.
Topics: Anticoagulants; Coumarins; Drug Therapy; Hemorrhage; Humans; Necrosis; Skin Diseases; Toxicology | 1965 |
[Vitamin K1-therapy in marcoumar hemorrhages].
Topics: Antifibrinolytic Agents; Coumarins; Hemorrhage; Humans; Naphthoquinones; Phenprocoumon; Retinoids; V | 1955 |
[Hemorrhage due to tromexan in eruption caused by penicillin].
Topics: Coumarins; Drug Eruptions; Ethyl Biscoumacetate; Exanthema; Hemorrhage; Humans; Penicillins; Tooth E | 1955 |
[Observations in the antithrombotic treatment of a female patient with varico-thrombophlebitis].
Topics: Breast; Breast Diseases; Coumarins; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intesti | 1955 |
Bleeding from unsupervised use of dicumarol.
Topics: Coumarins; Dicumarol; Hemorrhage; Humans | 1951 |
Severe hemorrhage due to tromexan; report of three cases.
Topics: Coumarins; Ethyl Biscoumacetate; Hemorrhage; Humans | 1951 |
Unusual hemorrhagic complications in dicumarol therapy.
Topics: Abdominal Wall; Coumarins; Dicumarol; Hemorrhage; Humans | 1951 |
Hemorrhage due to dicumarol and its analogues.
Topics: Coumarins; Dicumarol; Hemorrhage; Humans; Inorganic Chemicals | 1952 |
Establishing an optimal therapeutic range for coumarins: filling in the gaps.
Topics: Anticoagulants; Coumarins; Hemorrhage; Humans; International Normalized Ratio; Thromboembolism; Warf | 2004 |
Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Coumarins; Female; Heart Valve Prosthesis | 2004 |
Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cost-Benefit Analysis; Coumarin | 2004 |
Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.
Topics: Aged; Alanine; Amino Acid Substitution; Anticoagulants; Coumarins; Drug Hypersensitivity; Factor IX; | 2008 |
Leukocytoclastic vasculitis: another coumarin-induced hemorrhagic reaction.
Topics: Aged; Coumarins; Drug Eruptions; Hemorrhage; Humans; Male; Necrosis; Skin; Vasculitis, Leukocytoclas | 1994 |
Oral anticoagulant treatment in a medical care district--a descriptive study.
Topics: Administration, Oral; Anticoagulants; Coumarins; Female; Hemorrhage; Humans; Male; Monitoring, Ambul | 1995 |
[Retroperitoneal hematoma and femoral compression neuropathy--a complication of anticoagulation therapy after myocardial infarct].
Topics: Anticoagulants; Atrial Fibrillation; Cerebrovascular Disorders; Coumarins; Female; Hematoma; Hemorrh | 1998 |
Bleeding complication during coumarin therapy due to amiodarone and azithromycin.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Azithromycin; Coumarins; Drug Interactions; Fatal O | 2000 |
Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: identification of female alanine-10 valine heterozygotes.
Topics: Coumarins; Drug Hypersensitivity; Factor IX; Family Health; Female; Founder Effect; Hemorrhage; Hete | 2001 |
[An unusual complication of therapy with Pelentan--hemorrhage into the iliopsoas muscle].
Topics: Coumarins; Hemorrhage; Humans; Leg; Male; Middle Aged; Muscular Diseases; Tomography, X-Ray Computed | 1988 |
Anticoagulation is necessary in all patients with mechanical prostheses in sinus rhythm.
Topics: Anticoagulants; Bioprosthesis; Coumarins; Drug Therapy, Combination; Heart Valve Diseases; Heart Val | 1986 |
Coumarin induced acral skin necrosis associated with hereditary protein C deficiency.
Topics: Adult; Antigen-Antibody Complex; Cesarean Section; Complement C4; Coumarins; Female; Glycoproteins; | 1986 |